Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma

SIMPLE SUMMARY: Some metastatic renal cell carcinoma (mRCC) patients do not respond to immune checkpoint inhibitor (ICI) therapy. However, since predicting who will be a poor responder is difficult, a non-invasive, high-resolution genomic biomarker to accurately predict clinical responses to ICIs is...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagumo, Yoshiyuki, Kandori, Shuya, Kojima, Takahiro, Hamada, Kazuki, Nitta, Satoshi, Chihara, Ichiro, Shiga, Masanobu, Negoro, Hiromitsu, Mathis, Bryan J., Nishiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776722/
https://www.ncbi.nlm.nih.gov/pubmed/36551692
http://dx.doi.org/10.3390/cancers14246207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776722/
https://www.ncbi.nlm.nih.gov/pubmed/36551692
http://dx.doi.org/10.3390/cancers14246207

Ejemplares similares